Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000950170-25-041469

Options or other derivatives

  • Chief Executive Officer acquired 192,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
Kulkarni Samarth Chief Executive Officer 2025-03-14 Grant or award · Stock Option (Right to Buy) +110,000 110,000 D
Kulkarni Samarth Chief Executive Officer 2025-03-14 Grant or award · Restricted Stock Units +82,500 82,500 D
Loading xslF345X05/ownership.xml…